The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo

Neoplasia

Volumn 12, Issue 5, 2010, Pages 366-375

  Lyu, Mi Ae ^a   Rai, Deepak ^b   Ahn, Kwang Seok ^a   Sung, Bokyung ^a   Cheung, Lawrence H ^a   Marks, John W ^a   Aggarwal, Bharat B ^a   Aguiar, Ricardo C T ^b   Gandhi, Varsha ^a   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B CELL ACTIVATING FACTOR RECEPTOR; CASPASE 3; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN MCL 1; RECOMBINANT GELONIN B CELL ACTIVATING FACTOR FUSION TOXIN; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 77951694051     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91960     Document Type: Article

References (32)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511.
2. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, et al. (2003). The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102, 3871-3879.
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Eng J Med 346, 1937-1947.
4. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, and Staudt LM (2003). A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100, 9991-9996.
5. Abramson JS and Shipp MA (2005). Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106, 1164-1174.
6. Ghosh S, May MJ, and Kopp EB (1998). NF-κ B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16, 225-260.
7. Aggarwal BB (2004). Nuclearfactor-κB: the enemy within. CancerCell 6, 203-208.
8. Kucharczak J, Simmons MJ, Fan Y, and Gelinas C (2003). To be, or not to be: NF-κB is the answer-role of Rel/NF-κ B in the regulation of apoptosis. Oncogene 22, 8961-8982.
9. Wang CY, Guttridge DC, Mayo MW, and Baldwin AS (1999). NF-κB induces expression of the Bcl-2 homologue A1/BfI-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19, 5923-5929.
10. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, and Baldwin AS (1998). NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683.
11. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, and Franzoso G (2001). Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling. Nature 414, 308-313.
12. Karin M and Lin A (2002). NF-κB at the crossroads of life and death. Nat Immunol 3, 221-227.
13. Davis RE, Brown KD, Siebenlist U, and Staudt LM (2001). Constitutive nuclear factor B κ B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194, 1861-1874.
14. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L, et al. (2005). Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11, 28-40.
15. Rosenblum MG, Kohr WA, Beattie KL, Beattie WG, Marks W, Toman PD, and Cheung L (1995). Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum. J Interferon Cytokine Res 15, 547-555.
16. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, and Rosenblum MG (2002). In vitro and in vivo studies of a VEGF121/ rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 99, 7866-7871.
17. Lyu M-A, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, and Rosenblum MG (2007). The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 6, 460-470.
18. Nimmanapalli R, Lyu M-A, Du M, Keating MJ, Rosenblum MG, and Gandhi V (2007). The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood 109, 2557-2564.
19. Rai D, Karanti S, Jung I, Dahia PL, and Aguiar RC (2008). Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet 181, 8-15.
20. Chaturvesi MM, Mukhopadhyay A, and Aggarwal BB (2000). Assay for redoxsensitive factor. Methods Enzymol 319, 585-602.
21. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, et al. (2001). BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293, 2108-2111.
22. von Bulow GU and Bram RJ (1997). NFAT activation induced by a CAMLinteracting member of the tumor necrosis factor receptor superfamily. Science 278,138-141.
23. Laâbi Y, Gras MP, Carbonnel F, Brouet JC, Berger R, Larsen CJ, and Tsapis A (1992). A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16) (q26;p13) translocation in a malignant T cell lymphoma. EMBO J 11, 3897-3904.
24. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, and Cerutti A (2004). Lymphoma B cells evade apoptosis through the TNF family members BAFF/ BLyS and April. J Immunol 172, 3268-3279.
25. Novak AJ, Bram RJ, Kay NE, and Jelinek DF (2002). Aberrant expression of B-lymphocyte stimulator by B chronic leukemia cells: a mechanism for survival. Blood 100, 2973-2979.
26. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, et al. (2004). Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104, 2247-2253.
27. Nakamura N, Hase H, Sakurai D, Yoshida S, Abe M, Tsukada N, Takizawa J, Aoki S, Kojima M, Nakamura S, et al. (2005). Expression of BAFF-R (BR3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Arch 447, 53-60.
28. Paterson JC, Tedoldi S, Craxton A, Jones M, Hansmann ML, Collins G, Roberton H, Natkunam Y, Pileri S, Campo E, et al. (2006). The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. Haematologica 91, 772-780.
29. Kaisho T, Takeda K, Tsujimura T, Kawai T, Nomura F, Terada N, and Akira S (2001). IκB kinase α is essential for mature B cell development and function. J Exp Med 193, 417-426.
30. Pham LV, Tamayo AT, Yoshimura LC, Lo O, and Ford RJ (2003). Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171, 88-95.
31. Fu L, Lin-Lee Y-C, Pham LV, Tamayo A, Yoshimura L, and Ford RJ (2006). Constitutive NF-κB and NFATactivation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 107, 4540-4548.
32. Wong J, Korcheva V, Jacoby DB, and Magun BE (2007). Proinflammatory responses of human airway cells to ricin involve stress-activated protein kinases and NF-κB. Am J Physiol Lung Cell Mol Physiol 293, L1385-L1394.